Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Vermont: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 353 | 13% |
| 2020 | 5 | 387 | 16% |
| 2021 | 8 | 395 | 22% |
| 2022 | 7 | 278 | 30% |
| 2023 | 11 | 365 | 33% |
| 2024 | 10 | 397 | 35% |
| 2025 from claims | – | 428 346–502 | 34% |
| 2026 forecast | – | 579 454–727 | 14% |
| 2027 forecast | – | 631 468–835 | 10% |
| 2028 forecast | – | 687 487–949 | 7% |
| 2029 forecast | – | 748 508–1,072 | 4% |
| 2030 forecast | – | 812 532–1,205 | 1% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Vermont; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 134 | 7,123−2.3%/yr | −2.3%/yr | 4.0 | 10% | 7,020 in 2030−0.2%/yr |
| Pennsylvania | 164 | 6,776−2%/yr | −2%/yr | 5.0 | 12% | 6,810 in 2030+0.1%/yr |
| New Jersey | 109 | 6,001+1.1%/yr | +1.1%/yr | 5.8 | 31% | 7,770 in 2030+4.4%/yr |
| Maine | 11 | 5,521+56%/yr | +56%/yr | 35.4 | 0% | 540 in 2030−32%/yr |
| Massachusetts | 93 | 4,315−1.9%/yr | −1.9%/yr | 4.6 | 8% | 4,690 in 2030+1.4%/yr |
| Connecticut | 39 | 1,628−1.4%/yr | −1.4%/yr | 5.0 | 4% | 1,890 in 2030+2.5%/yr |
| New Hampshire | 22 | 921−1.3%/yr | −1.3%/yr | 4.1 | 2% | 1,150 in 2030+3.8%/yr |
| Rhode Island | 9 | 436−3.7%/yr | −3.7%/yr | 4.9 | 0% | 440 in 2030+0.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 3 | 213−6.2%/yr | −6.2%/yr | 1.90.4× | 0% | 320 in 2030+7.2%/yr |
| Hysterectomy, hysteroscopy & ablation | 4 | 193−5.7%/yr | −5.7%/yr | 1.80.5× | 9% | 360 in 2030+11%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Vermont · Every state · Compare with New York
No company payments named for these products in Vermont in 2025.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.